Clinical trials
CIDP clinical trials
Below are recruiting cidp clinical trials, each written for real people, not researchers. We’re tracking 28 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07264426Recruiting
Real-world study of efgartigimod for CIDP
This study looks at how well efgartigimod works in everyday use for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to understand the real-world benefits of this treatment.
Wilmington, North CarolinaAges 18 years+ - NCT06920004RecruitingPhase 3
Testing empasiprubart vs IVIg for chronic CIDP
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
Birmingham, AlabamaAges 18 years+ - NCT04589299RecruitingPhase 4
Subcutaneous immune globulin for newly diagnosed CIDP
This study tests whether giving immune globulin under the skin (SCIG) can help people with newly diagnosed CIDP. It may help improve muscle strength and nerve symptoms while avoiding the need for earlier IVIG/SCIG treatment.
AalborgAges 18 years+ - NCT07461896Recruiting
Nerve function study in Charcot-Marie-Tooth and related neuropathies
This study looks at how nerves work and their structure in people with Charcot-Marie-Tooth disease, CIDP, or anti-MAG neuropathy. It may help doctors better understand these conditions.
MilanAges 18 years+ - NCT07273903Recruiting
Tracking CIDP treatment with a smartwatch
This trial tests whether a smartwatch can help monitor how well subcutaneous immunoglobulin (fSCIG) works for people with CIDP who recently switched from IVIG or plan to switch. It aims to make treatment tracking easier and more convenient.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT07091630RecruitingPhase 3
A study of empasiprubart for chronic inflammatory demyelinating polyneuropathy (CIDP)
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
Birmingham, AlabamaAges 18 years+ - NCT06798012RecruitingPhase 2
TAK-411 for adults with CIDP
This study tests a new investigational drug called TAK-411 for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). It is for people who have already responded to immunoglobulin therapy and are on a stable dose.
La Jolla, CaliforniaAges 18 years+ - NCT06747351RecruitingPhase 3
Comparing two immune globulin treatments for CIDP
This study tests if TAK-881 is as safe and effective as HYQVIA for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). You may join if you have been stable on immune globulin therapy and have certain disability levels.
Scottsdale, ArizonaAges 18 years+ - NCT06538064Recruiting
Study of HyQvia for Adults with CIDP in Routine Care
This study looks at how well HyQvia works for adults with CIDP in everyday medical practice. It includes people who are already using HyQvia or are switching to it.
Rancho Mirage, CaliforniaAges 18 years+ - NCT05584631RecruitingPhase 1
Switching IVIG to weekly SCIG for CIDP treatment
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
New Brunswick, New JerseyAges 18–65 - NCT04881682RecruitingPhase 2
Testing blood-cleansing vs immunoglobulin for CIDP
This Phase 2 study compares a blood-cleansing treatment (immunoadsorption) with standard immune-boosting treatment (intravenous immunoglobulins) for chronic inflammatory demyelinating polyneuropathy (CIDP). It may help people whose steroid treatment did not work well, or who cannot take steroids.
Ulm, Baden-WurttembergAges 18 years+ - NCT03684018RecruitingPhase 4
Testing two doses of Privigen for children with CIDP
This study tests whether two different dose levels of Privigen (a type of immune blood treatment) are safe and effective for children and teens with CIDP. It may help improve nerve-related symptoms in people whose CIDP has been confirmed or is being evaluated as likely.
Phoenix, ArizonaAges 2–17 - NCT06714838RecruitingPhase 3
Rituximab for remission in chronic inflammatory demyelinating polyneuropathy
This trial tests a drug called rituximab to see if it can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) achieve remission. It may offer a new treatment option for those who are newly diagnosed or who are on maintenance therapy with wear-off symptoms or failed withdrawal attempts.
AmsterdamAges 18–80 - NCT07540221RecruitingPhase 3
Comparing two immune therapy infusions for nerve damage
This study tests whether a new immune therapy called XEMBIFY works as well as a standard treatment (Gamunex-C) for CIDP, a condition where the immune system damages nerves and causes weakness. Both are given as infusions under the skin every three weeks.
Rancho Mirage, CaliforniaAges 18 years+ - NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75 - NCT06183645Recruiting
Predicting CIDP decline during IVIg treatment changes
This study looks at people with CIDP who are stable on IVIg treatment to see if we can predict when they might get worse if their treatment is adjusted. It aims to make treatment management easier and more personalized.
Liège, LiègeAges 18–99 - NCT07337785RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
Wuhan, HubeiAges 18–70 - NCT07154524Recruiting
Immunoadsorption for CIDP treatment study
This trial tests whether a blood-filtering treatment called immunoadsorption can help people with CIDP. It is for adults who are already receiving or starting IVIg or MP therapy.
Ulm, Baden-WurttembergAges 18 years+ - NCT05004493Recruiting
Plasma exchange patient registry and sample collection
This study collects information and blood or other samples from people who are getting plasma exchange therapy. The goal is to build a registry (a organized database) that researchers can use to better understand and improve care.
Iowa City, IowaAges 12–99 - NCT07032662RecruitingPhase 2
Study of imeroprubart for chronic inflammatory demyelinating polyneuropathy (CIDP)
This trial tests whether a new medicine called imeroprubart can help people with CIDP, a nerve condition causing weakness and numbness. It may provide an alternative to current treatments like steroids or immunoglobulin therapy.
Tucson, ArizonaAges 18 years+ - NCT06968975Recruiting
Real-world study of CIDP treatment outcomes
This study looks at how well current treatments work for people with CIDP (a nerve condition causing weakness). It tracks symptoms and daily function over time to help doctors understand which treatments may work best.
Swiftwater, PennsylvaniaAges 18 years+ - NCT06859099Enrolling by invitationPhase 3
Long-term safety study of Riliprubart for CIDP
This study checks the long-term safety and how well riliprubart works for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It is for those who have already taken riliprubart in a previous study.
Homewood, AlabamaAges 18 years+ - NCT06752356RecruitingPhase 3
A study of a new IVIG treatment for CIDP
This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.
Stamford, ConnecticutAges 18 years+ - NCT06615622Recruiting
Using ultrasound to detect nerve changes in GBS and CIDP
This study tests if ultrasound can find nerve problems in people with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP), and if it helps doctors diagnose and predict outcomes early.
AsyutAges 18–75
Hear when a new CIDP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cidp?
- Yes. Clin2 currently lists 28 recruiting cidp studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cidp trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cidp trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.